Format
Sort by
Items per page

Send to

Choose Destination

Search results

Items: 26

1.

Small extracellular vesicles containing arginase-1 suppress T-cell responses and promote tumor growth in ovarian carcinoma.

Czystowska-Kuzmicz M, Sosnowska A, Nowis D, Ramji K, Szajnik M, Chlebowska-Tuz J, Wolinska E, Gaj P, Grazul M, Pilch Z, Zerrouqi A, Graczyk-Jarzynka A, Soroczynska K, Cierniak S, Koktysz R, Elishaev E, Gruca S, Stefanowicz A, Blaszczyk R, Borek B, Gzik A, Whiteside T, Golab J.

Nat Commun. 2019 Jul 5;10(1):3000. doi: 10.1038/s41467-019-10979-3.

2.

Biological markers of prognosis, response to therapy and outcome in ovarian carcinoma.

Szajnik M, Czystowska-Kuźmicz M, Elishaev E, Whiteside TL.

Expert Rev Mol Diagn. 2016 Aug;16(8):811-26. doi: 10.1080/14737159.2016.1194758. Epub 2016 Jun 23. Review.

3.

Antagonism of tumoral prolactin receptor promotes autophagy-related cell death.

Wen Y, Zand B, Ozpolat B, Szczepanski MJ, Lu C, Yuca E, Carroll AR, Alpay N, Bartholomeusz C, Tekedereli I, Kang Y, Rupaimoole R, Pecot CV, Dalton HJ, Hernandez A, Lokshin A, Lutgendorf SK, Liu J, Hittelman WN, Chen WY, Lopez-Berestein G, Szajnik M, Ueno NT, Coleman RL, Sood AK.

Cell Rep. 2014 Apr 24;7(2):488-500. doi: 10.1016/j.celrep.2014.03.009. Epub 2014 Apr 3.

4.

Exosomes in Plasma of Patients with Ovarian Carcinoma: Potential Biomarkers of Tumor Progression and Response to Therapy.

Szajnik M, Derbis M, Lach M, Patalas P, Michalak M, Drzewiecka H, Szpurek D, Nowakowski A, Spaczynski M, Baranowski W, Whiteside TL.

Gynecol Obstet (Sunnyvale). 2013 Apr 29;Suppl 4:3.

5.

17β Hydroxysteroid dehydrogenase type 12 (HSD17B12) is a marker of poor prognosis in ovarian carcinoma.

Szajnik M, Szczepanski MJ, Elishaev E, Visus C, Lenzner D, Zabel M, Glura M, DeLeo AB, Whiteside TL.

Gynecol Oncol. 2012 Dec;127(3):587-94. doi: 10.1016/j.ygyno.2012.08.010. Epub 2012 Aug 17.

6.

A gynecologic oncology group phase II trial of two p53 peptide vaccine approaches: subcutaneous injection and intravenous pulsed dendritic cells in high recurrence risk ovarian cancer patients.

Rahma OE, Ashtar E, Czystowska M, Szajnik ME, Wieckowski E, Bernstein S, Herrin VE, Shams MA, Steinberg SM, Merino M, Gooding W, Visus C, Deleo AB, Wolf JK, Bell JG, Berzofsky JA, Whiteside TL, Khleif SN.

Cancer Immunol Immunother. 2012 Mar;61(3):373-84. doi: 10.1007/s00262-011-1100-9. Epub 2011 Sep 17.

7.

Blast-derived microvesicles in sera from patients with acute myeloid leukemia suppress natural killer cell function via membrane-associated transforming growth factor-beta1.

Szczepanski MJ, Szajnik M, Welsh A, Whiteside TL, Boyiadzis M.

Haematologica. 2011 Sep;96(9):1302-9. doi: 10.3324/haematol.2010.039743. Epub 2011 May 23.

8.

Mechanisms of tumor escape from the immune system: adenosine-producing Treg, exosomes and tumor-associated TLRs.

Whiteside TL, Mandapathil M, Szczepanski M, Szajnik M.

Bull Cancer. 2011 Feb;98(2):E25-31. doi: 10.1684/bdc.2010.1294. Review.

9.

Mechanisms of T-cell protection from death by IRX-2: a new immunotherapeutic.

Czystowska M, Szczepanski MJ, Szajnik M, Quadrini K, Brandwein H, Hadden JW, Whiteside TL.

Cancer Immunol Immunother. 2011 Apr;60(4):495-506. doi: 10.1007/s00262-010-0951-9. Epub 2010 Dec 23.

10.

[Expression of survivin, SDF-1 and CXCR4 on tumor cells in ovarian cancer].

Nowak-Markwitz E, Puła B, Szajnik M, Dziegiel P, Piotrowska A, Zabel M, Spaczyński M.

Ginekol Pol. 2010 Sep;81(9):674-7. Polish.

PMID:
20973204
11.

Tumor-derived microvesicles induce, expand and up-regulate biological activities of human regulatory T cells (Treg).

Szajnik M, Czystowska M, Szczepanski MJ, Mandapathil M, Whiteside TL.

PLoS One. 2010 Jul 22;5(7):e11469. doi: 10.1371/journal.pone.0011469.

12.

Adenosine and prostaglandin E2 cooperate in the suppression of immune responses mediated by adaptive regulatory T cells.

Mandapathil M, Szczepanski MJ, Szajnik M, Ren J, Jackson EK, Johnson JT, Gorelik E, Lang S, Whiteside TL.

J Biol Chem. 2010 Sep 3;285(36):27571-80. doi: 10.1074/jbc.M110.127100. Epub 2010 Jun 17.

13.

Regulatory T cell suppression of Gag-specific CD8 T cell polyfunctional response after therapeutic vaccination of HIV-1-infected patients on ART.

Macatangay BJ, Szajnik ME, Whiteside TL, Riddler SA, Rinaldo CR.

PLoS One. 2010 Mar 24;5(3):e9852. doi: 10.1371/journal.pone.0009852.

14.

Reciprocal granzyme/perforin-mediated death of human regulatory and responder T cells is regulated by interleukin-2 (IL-2).

Czystowska M, Strauss L, Bergmann C, Szajnik M, Rabinowich H, Whiteside TL.

J Mol Med (Berl). 2010 Jun;88(6):577-88. doi: 10.1007/s00109-010-0602-9. Epub 2010 Mar 12.

15.

Generation and accumulation of immunosuppressive adenosine by human CD4+CD25highFOXP3+ regulatory T cells.

Mandapathil M, Hilldorfer B, Szczepanski MJ, Czystowska M, Szajnik M, Ren J, Lang S, Jackson EK, Gorelik E, Whiteside TL.

J Biol Chem. 2010 Mar 5;285(10):7176-86. doi: 10.1074/jbc.M109.047423. Epub 2009 Oct 26.

16.

TLR4 signaling induced by lipopolysaccharide or paclitaxel regulates tumor survival and chemoresistance in ovarian cancer.

Szajnik M, Szczepanski MJ, Czystowska M, Elishaev E, Mandapathil M, Nowak-Markwitz E, Spaczynski M, Whiteside TL.

Oncogene. 2009 Dec 10;28(49):4353-63. doi: 10.1038/onc.2009.289.

17.

Increased ectonucleotidase expression and activity in regulatory T cells of patients with head and neck cancer.

Mandapathil M, Szczepanski MJ, Szajnik M, Ren J, Lenzner DE, Jackson EK, Gorelik E, Lang S, Johnson JT, Whiteside TL.

Clin Cancer Res. 2009 Oct 15;15(20):6348-57. doi: 10.1158/1078-0432.CCR-09-1143. Epub 2009 Oct 13.

18.

Tumor-derived microvesicles promote regulatory T cell expansion and induce apoptosis in tumor-reactive activated CD8+ T lymphocytes.

Wieckowski EU, Visus C, Szajnik M, Szczepanski MJ, Storkus WJ, Whiteside TL.

J Immunol. 2009 Sep 15;183(6):3720-30. doi: 10.4049/jimmunol.0900970. Epub 2009 Aug 19.

19.

Differential responses of human regulatory T cells (Treg) and effector T cells to rapamycin.

Strauss L, Czystowska M, Szajnik M, Mandapathil M, Whiteside TL.

PLoS One. 2009 Jun 22;4(6):e5994. doi: 10.1371/journal.pone.0005994.

20.

Interleukin-15 enhances natural killer cell cytotoxicity in patients with acute myeloid leukemia by upregulating the activating NK cell receptors.

Szczepanski MJ, Szajnik M, Welsh A, Foon KA, Whiteside TL, Boyiadzis M.

Cancer Immunol Immunother. 2010 Jan;59(1):73-9. doi: 10.1007/s00262-009-0724-5. Epub 2009 Jun 13.

21.

Biological significance of prolactin in gynecologic cancers.

Levina VV, Nolen B, Su Y, Godwin AK, Fishman D, Liu J, Mor G, Maxwell LG, Herberman RB, Szczepanski MJ, Szajnik ME, Gorelik E, Lokshin AE.

Cancer Res. 2009 Jun 15;69(12):5226-33. doi: 10.1158/0008-5472.CAN-08-4652. Epub 2009 Jun 2.

22.

Increased frequency and suppression by regulatory T cells in patients with acute myelogenous leukemia.

Szczepanski MJ, Szajnik M, Czystowska M, Mandapathil M, Strauss L, Welsh A, Foon KA, Whiteside TL, Boyiadzis M.

Clin Cancer Res. 2009 May 15;15(10):3325-32. doi: 10.1158/1078-0432.CCR-08-3010. Epub 2009 May 5.

23.

Role of eotaxin-1 signaling in ovarian cancer.

Levina V, Nolen BM, Marrangoni AM, Cheng P, Marks JR, Szczepanski MJ, Szajnik ME, Gorelik E, Lokshin AE.

Clin Cancer Res. 2009 Apr 15;15(8):2647-56. doi: 10.1158/1078-0432.CCR-08-2024. Epub 2009 Apr 7.

24.

Triggering of Toll-like receptor 4 expressed on human head and neck squamous cell carcinoma promotes tumor development and protects the tumor from immune attack.

Szczepanski MJ, Czystowska M, Szajnik M, Harasymczuk M, Boyiadzis M, Kruk-Zagajewska A, Szyfter W, Zeromski J, Whiteside TL.

Cancer Res. 2009 Apr 1;69(7):3105-13. doi: 10.1158/0008-5472.CAN-08-3838. Epub 2009 Mar 24.

25.

IRX-2, a novel immunotherapeutic, protects human T cells from tumor-induced cell death.

Czystowska M, Han J, Szczepanski MJ, Szajnik M, Quadrini K, Brandwein H, Hadden JW, Signorelli K, Whiteside TL.

Cell Death Differ. 2009 May;16(5):708-18. doi: 10.1038/cdd.2008.197. Epub 2009 Jan 30.

26.

[Assessment of expression of luteinizing hormone (LH)/human chorionic gonadotropin (hCG) receptor (LH/hCGR) and hCG protein in ovarian cancer tissues].

Szajnik M, Nowak-Markwitz E, Szczepański MJ, Spaczyński M.

Ginekol Pol. 2007 Dec;78(12):939-43. Polish.

PMID:
18411916

Supplemental Content

Loading ...
Support Center